Considering the potential role of Angiotensin II (Ang II), a well-known target for hypertension treatment, in the induction of NETosis and its associated fibrotic damage, the Ang II receptor blocker (ARB) Telmisartan has undergone small-scale clinical trials to assess its utility in MASH treatment [171,172]. This evidence concerns the gene AGT and metabolic dysfunction-associated steatohepatitis.